Braf
Entity.
- Evidence
- 123 documents · 53 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 15 Mar 2026, last seen 8 Oct 2026
- Measured
- 11% of mentions say something specific about it; the rest only name it
- As of
- 8 Oct 2026
Where this comes from
- Frontiers Precision Oncology · 2026-10-02 · Systemic treatment strategies for BRAF wild-type metastatic unresectable melanoma: a network meta-analysis (opens the source in a new tab)
- Colorectal Dis · 2026-10-01 · Systemic inflammation and prognosis in patients with RAS/BRAF wild-type metastatic colorectal cancer receiving anti-EGFR therapy: A real-world cohort study. (opens the source in a new tab)
- Anticancer Drugs · 2026-09-30 · Pathologic complete response after first-line tislelizumab, cetuximab, and dabrafenib in microsatellite-stable BRAF V600E-mutant metastatic colorectal cancer: a case r… (opens the source in a new tab)
- The ASCO Post · 2026-09-22 · BRAF Class Alterations in NSCLC Have Different Characteristics, Outcomes, and Co-Mutations, Research Shows (opens the source in a new tab)
- Inside Precision Medicine · 2026-09-15 · BRAF Mutation Class Influences Outcomes in NSCLC (opens the source in a new tab)
- Journal of Clinical Oncology · 2026-09-13 · Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of t… (opens the source in a new tab)
- Annals of Oncology · 2026-09-13 · A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3 (opens the source in a new tab)
- Clinical Colorectal Cancer · 2026-09-11 · Successful Encorafenib and Cetuximab Re-Challenge Combined With Nivolumab in BRAF V600E Mutated, Mismatch-Repair-Proficient Metastatic Colorectal Cancer – A … (opens the source in a new tab)
- J Dermatol · 2026-09-04 · Eruptive Melanocytic Nevi Associated With Encorafenib and Cetuximab Therapy in Two Patients With BRAF V600E-Mutated Colorectal Cancer. (opens the source in a new tab)
- crc-digest · 2026-09-03 · Real-World Data on Encorafenib Plus Panitumumab in BRAF V600E Metastatic CRC (opens the source in a new tab)
- Clin Colorectal Cancer · 2026-09-02 · Population-Based Multicenter Real-World Outcomes of Encorafenib Plus Panitumumab in BRAF V600E-Mutated Metastatic Colorectal Cancer. (opens the source in a new tab)